Kangkang Yu

ORCID: 0000-0003-3509-0977
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Hepatitis B Virus Studies
  • Liver Disease Diagnosis and Treatment
  • Hepatitis C virus research
  • MicroRNA in disease regulation
  • Liver Disease and Transplantation
  • Ferroptosis and cancer prognosis
  • Cancer Mechanisms and Therapy
  • Cancer, Hypoxia, and Metabolism
  • HIV/AIDS drug development and treatment
  • RNA modifications and cancer
  • Liver physiology and pathology
  • Metabolomics and Mass Spectrometry Studies
  • Circular RNAs in diseases
  • Drug-Induced Hepatotoxicity and Protection
  • Cytokine Signaling Pathways and Interactions
  • Liver Diseases and Immunity
  • Cancer-related molecular mechanisms research
  • RNA Interference and Gene Delivery
  • Cancer, Lipids, and Metabolism
  • COVID-19 diagnosis using AI
  • Streptococcal Infections and Treatments
  • Neutrophil, Myeloperoxidase and Oxidative Mechanisms
  • Systemic Lupus Erythematosus Research
  • Pancreatic and Hepatic Oncology Research
  • Atrial Fibrillation Management and Outcomes

Fudan University
2016-2025

Huashan Hospital
2016-2025

Shanghai University
2010-2023

National Institute for Communicable Disease Control and Prevention
2022

Shanghai Medical College of Fudan University
2022

Memorial Sloan Kettering Cancer Center
2021

Yale University
2020

National Natural Science Foundation of China
2017

Luohe Medical College
2015

Shanghai University of Engineering Science
2011

Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 infection, has been spreading globally. We aimed to develop a clinical model predict the outcome of patients with COVID-19 infection early.Demographic, and first laboratory findings after admission 183 (115 survivors 68 non-survivors from Sino-French New City Branch Tongji Hospital, Wuhan) were used predictive models. Machine learning approaches select features patients' outcomes. The area under...

10.1093/ije/dyaa171 article EN other-oa International Journal of Epidemiology 2020-08-11

Abstract The identification of serum biomarkers to improve the diagnosis and prognosis hepatocellular carcinoma has been elusive date. In this study, we took a mass spectroscopic approach characterize metabolic features liver in patients discover more sensitive specific for progression. Global profiling 50 pairs matched tissue samples from was performed. A series 62 metabolites were found be altered significantly tumors; however, levels acetylcarnitine correlated most strongly with tumor...

10.1158/0008-5472.can-15-3199 article EN Cancer Research 2016-03-15

Abstract Background Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has been spreading globally. The number of deaths increased with the increase in infected patients. We aimed to develop a clinical model predict outcome COVID-19 patients early. Methods Epidemiological, clinical, and first laboratory findings after admission 183 (115 survivors 68 nonsurvivors) from Sino-French New City Branch Tongji Hospital were used...

10.1101/2020.04.13.20064329 preprint EN cc-by-nc-nd medRxiv (Cold Spring Harbor Laboratory) 2020-04-19

Abstract Background Hepatocellular carcinoma (HCC) is closely associatedwith chronic liver diseases, particularly cirrhosis, which has an altered extracellular matrix (ECM) composition. The influence and its mechanism of the cirrhotic-ECM on response HCC to immune checkpoint inhibitor (ICI) remains less clarified. Methods In silico, proteomic pathological assessment alteration were applied in clinical cohort. Multiple pre-clinical models with ECM manipulation used evaluate cirrhotic-ECM’s...

10.1186/s40164-024-00476-9 article EN cc-by Experimental Hematology and Oncology 2024-02-22

We compared hepatic and serum lipid changes in hepatocellular carcinoma (HCC) patients to have a better understanding of the molecular pathogenesis this disease discovery novel biomarkers. Hepatic profiling was conducted paired liver samples from 50 HCC 24 healthy controls. A total 20 40 signatures were identified, yet there hardly any significant correlation between them. The results indicated that triglycerides phosphatidylcholines contributed significantly altered lipids, whereas...

10.18632/oncotarget.23494 article EN Oncotarget 2017-12-13

Background/Aims: To investigate the role of selected serum microRNA (miRNA) levels as potential noninvasive biomarkers for differentiating S0-S2 (early fibrosis) from S3-S4 (late in patients with a chronic hepatitis B virus (HBV) infection.Methods: One hundred twenty-three treatmentnaive HBV infection who underwent liver biopsy were enrolled this study.The miRNAs measured using real-time quantitative polymerase chain reaction assay.A logistic regression analysis was performed to assess...

10.5009/gnl16560 article EN cc-by-nc Gut and Liver 2017-07-27

Unlike other malignancies, therapeutic options in pancreatic ductal adenocarcinoma (PDAC) are largely limited to cytotoxic chemotherapy without the benefit of molecular markers predicting response. Here we report tumor-cell-intrinsic chromatin accessibility patterns treatment-naïve surgically resected PDAC tumors that were subsequently treated with (Gem)/Abraxane adjuvant chemotherapy. By ATAC-seq analyses EpCAM+ malignant epithelial cells sorted from 54 freshly human tumors, show here...

10.1038/s41467-021-23237-2 article EN cc-by Nature Communications 2021-05-24

Tyrosine kinase inhibitor resistance is a key factor affecting the prognosis of patients with advanced hepatocellular carcinoma (HCC). Previously, our group demonstrated that HCC high stomatin-like protein 2 (STOML2) expression were poorly sensitive to systemic therapy. Whether STOML2 involved in sorafenib unclear. Recent mechanistic studies have selective activation ferroptosis pathways expected restore sensitivity. The aim present study was investigate STOML2-ferroptosis axis and its...

10.62347/sutj3506 article EN American Journal of Cancer Research 2025-01-01

Background: Hepatocellular carcinoma (HCC) is a kind of fatal cancer with va-riety risk factors. However, pan-etiology molecular characterization HCC has not been explored. Objective: The objective this study to explore etiology-specific features and im-prove our understanding tumorigenesis, thereby revealing potential therapeutic targets. Methods: RNA-seq, genetic alteration, copy number clinicopathological data Cancer Genome Atlas -Liver Carcinoma cohort were downloaded Immune-related...

10.2174/0115680096370558250514063841 article EN Current Cancer Drug Targets 2025-05-22

Acute-on-chronic liver failure (ACLF) in chronic hepatitis B (CHB) patients has a high short-term mortality. Identification of effective models to predict the mortality may enable early intervention and improve patients' prognosis. We aim assess performance CLIF Consortium Organ Failure score (CLIF-C OFs), sequential organ assessment (CLIF-SOFAs), ACLF ACLFs), grade, model for end-stage disease (MELDs) predicting CHB with ACLF. Among 155 consecutive adult as discharge diagnosis were...

10.1097/md.0000000000006802 article EN cc-by-nc Medicine 2017-04-01

Abstract Based on molecular profiling, several prognostic markers for HCC are also used in clinic, but only a few genes have been identified as useful. We collected 72 post-operative liver cancer tissue samples. Genes expression were tested by RT-PCR. Multilayer perceptron and discriminant analysis built their ability to predict the prognosis of patients tested. Receiver operating characteristic (ROC) was performed multivariate with Cox’s Proportional Hazard Model confirming...

10.1038/srep24582 article EN cc-by Scientific Reports 2016-04-15

Abstract Background The purpose of this study is to investigate whether or not the complement system systemically activated and specify clinical prognostic implications its components during hepatitis B virus related acute-on-chronic liver failure (HBV-ACLF). Methods Blood samples were taken from twenty-seven patients diagnosed with HBV-ACLF, twenty-five chronic but without (CHB), nine healthy volunteers (the control group). Plasma measured Enzyme-linked immunosorbent assay. Correlative...

10.1186/s12876-020-01258-3 article EN cc-by BMC Gastroenterology 2020-04-15

Dual oxidase 1 (DUOX1), which is the main source of reactive oxygen species (ROS) production in airway, can be silenced human lung cancer and hepatocellular carcinomas. However, prognostic value DUOX1 expression carcinoma patients still unclear. We investigated liver patients. mRNA was determined tumor tissues non-tumor by real‑time PCR. For evaluation expression, Kaplan-Meier method Cox's proportional hazards model (univariate analysis multivariate analysis) were employed. A simple risk...

10.3892/or.2016.4745 article EN cc-by-nc-nd Oncology Reports 2016-04-14

Acute myeloid leukemia (AML) is the most common leukemia. It highly malignant, thus, patients with AML will relapse and die after traditional treatment. Stat3, a member of signal transducer activator transcription (Stat) family, involved in development progression many tumors. The purpose study was to investigate whether down-regulation Stat3 expression by RNA interference effective against human HL-60 cells. results indicated that constitutively expressed present cells, caused significant...

10.1179/102453311x13025568941925 article EN Hematology 2011-07-01

Hepatocellular carcinoma (HCC) is a significant health burden worldwide and its pathogenesis remains to be fully elucidated. One of the means by which long non-coding (lnc)RNAs regulate gene expression interacting with micro (mi)RNAs acting as competing endogenous (ce)RNAs. lncRNAs have important roles in various diseases. The aim present study was examine potential HCC. RNA profiles 21 paired tissues HCC adjacent non-tumor were obtained from Gene Expression Omnibus database. differentially...

10.3892/etm.2019.8046 article EN Experimental and Therapeutic Medicine 2019-09-25
Coming Soon ...